Clinical Trial to Evaluate the Efficacy and Safety of CKD-342

NCT02498509 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 459

Last updated 2016-12-26

No results posted yet for this study

Summary

Clinical Trial to Evaluate the Efficacy and Safety of CKD-342

Conditions

  • Rhinitis, Allergic, Perennial

Interventions

DRUG

CKD-342

treatment for 4 weeks after randomization

DRUG

Mometasone furoate

treatment for 4 weeks after randomization

DRUG

Levocabastine HCL

treatment for 4 weeks after randomization

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-03-31
Completion
2016-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02498509 on ClinicalTrials.gov